Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Novel Antisense Compound Reverses Alzheimer's Disease Symptoms in Mouse Models

By BiotechDaily International staff writers
Posted on 02 Jun 2014
An antisense oligonucleotide, which suppresses the mRNA required for synthesis of amyloid-beta protein precursor (AbetaPP), decreased AbetaPP expression and amyloid-beta protein (Abeta) production, and reversed Alzheimer's disease symptoms in mouse models.

Investigators at Saint Louis University (MO, USA) had shown previously that their OL-1 antisense compound rapidly crossed the blood-brain barrier, reversed learning and memory impairments, reduced oxidative stress, and restored brain-to-blood efflux of Abeta in the SAMP8 mouse model. These animals carry a natural mutation causing them to overproduce mouse amyloid beta.

In the current study, the investigators tested OL-1 in the Tg2576 Alzheimer's disease mouse model, which comprises animals that had been genetically engineered to overexpress a mutant form of the human amyloid beta precursor gene.

Results published in the May 2014 issue of the Journal of Alzheimer's Disease revealed that treatment of the Tg2576 mice with OL-1 produced the same reversal of Alzheimer's disease symptoms as had been observed earlier in the SAMP8 mice. Biochemical analyses of brain tissue taken from the treated animals showed significant reduction of AbetaPP signaling and a reduction of indicators of neuroinflammation.

"Our findings reinforced the importance of amyloid beta protein in the Alzheimer's disease process. They suggest that an antisense that targets the precursor to amyloid beta protein is a potential therapy to explore to reversing symptoms of Alzheimer's disease," said senior author Dr. Susan Farr, professor of geriatrics at Saint Louis University. "It reversed learning and memory deficits and brain inflammation in mice that are genetically engineered to model Alzheimer's disease. Our current findings suggest that the compound, which is called antisense oligonucleotide (OL-1), is a potential treatment for Alzheimer's disease."

Related Links:

Saint Louis University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.